我们应该如何靶向和减少IgA肾病中致病性IgA的产生?
IgA肾病是最常见的原发性肾小球肾炎,以肾功能进行性下降为特征。本文综述了针对致病性IgA产生的治疗策略,包括靶向黏膜B细胞 priming、APRIL和B细胞激活因子抑制剂以及靶向产生IgA的浆细胞的药物,并总结了这些策略的新兴临床数据。
要点
- IgA肾病全球范围内最常见的原发性肾小球肾炎,大量患者一生中可进展至肾衰竭。
- 多打击模型:循环中升高的半乳糖缺陷型IgA1(Gd-IgA1)可能来源于黏膜,被自身抗体识别形成致病性免疫复合物沉积于肾小球系膜。
- 正在开发的靶向致病性IgA产生的治疗包括靶向黏膜B细胞 priming、APRIL和B细胞激活因子抑制剂以及靶向产生IgA的浆细胞的药物。
核心结论
- 多种靶向致病性IgA产生的治疗策略正在开发中,并已涌现出临床数据。
研究设计与样本
- 综述,描述了IgA的产生并总结了针对致病性IgA产生策略的新兴临床数据。
主要发现
- IgA肾病以肾功能进行性下降为特征,大量患者一生中可发展至肾衰竭。
- 多打击模型已建立:循环中升高的半乳糖缺陷型IgA1(Gd-IgA1)可能来源于黏膜,被自身抗体识别,形成致病性免疫复合物沉积于肾小球系膜,导致后续炎症和损伤。
- 正在开发的治疗包括靶向黏膜B细胞 priming、APRIL和B细胞激活因子抑制剂以及靶向产生IgA的浆细胞的药物。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IgA nephropathy represents the most common primary glomerulonephritis worldwide and is characterized by a progressive decline in kidney function, with a large proportion of patients developing kidney failure within their lifetime. Significant progress in the understanding of its pathogenesis has led to a multi-hit model being established, where elevated levels of galactose-deficient-IgA1 (Gd-IgA1), probably from a mucosal source, are found in the circulation and recognized by autoantibodies, leading to the formation of pathogenic immune complexes that deposit within the glomerular mesangium, and subsequent inflammation and damage. Several therapies are currently being developed in IgAN that target the production of pathogenic IgA, including those directed at mucosal B cell priming, inhibitors of the B cell survival mediators APRIL and B cell activation factor, and drugs that target IgA-producing plasma cells. In this review, we describe the production of IgA and summarize the emerging clinical data arising from these strategies.
引用
- Cheung CK, Suzuki Y. How should we target and reduce the production of pathogenic IgA in IgAN? Nephrol Dial Transplant. 2026. PMID: 40985586. doi:10.1093/ndt/gfaf185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。